gastric cancer
Elevation Oncology Narrows EO-3021 Trial to Claudin 18.2-Expressing Patients, Launches Combo Cohorts
The firm is using immunohistochemistry to gauge biomarker expression before enrolling patients in a trial of its CLDN 18.2-directed antibody-drug conjugate.
I-Mab Streamlines Operations, Focuses Pipeline on CLDN18.2-Directed Therapy
The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.
BeiGene Nabs FDA Approval for Tevimbra With Chemo in First-Line PD-L1-Positive Gastric Cancer
Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.
Carsgen to Seek Approval in China for Satri-Cel in Claudin18.2-Expressing Gastric Cancer
The firm said the Phase III trial met its primary endpoint of improvement in progression-free survival.
Accent Therapeutics Treats First Patient in Phase I DHX9 Inhibitor Trial
The study is designed to evaluate the safety, tolerability, and preliminary efficacy of ATX-559 in certain biomarker-selected cancer patients.